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Introduction
Activating epidermal growth factor receptor (EGFR) mutations predict sensitivity to first-and second-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, icotinib and afatinib with higher overall response rate (ORR) and progression-free survival (PFS) compared with upfront platinum doublet chemotherapy, making them the standard of care [1, 2] . However, tumours invariably develop acquired resistance (AR) $9-12 months after treatment initiation [1] . Several mechanisms of AR have been reported, such as secondary EGFR mutations, bypass track signalling pathways and histologic transformation [3] .
The substitution of threonine to methionine at amino acid position 790 (T790M) in exon 20 of the EGFR gene reduces first-generation EGFR TKIs binding by enhancing the ATP binding affinity of the kinase domain of the EGFR-mutant receptor [4] . This mutation accounts for AR in $50%-60% of the patients [3, 5] . MET amplification is the second most common mechanism of AR to EGFR TKIs in up to 20% of cases [6] irrespective of the T790M mutational status [7] . Histologic transformation to small-cell lung cancer (SCLC) accounts for 5%-10% of EGFR-mutant tumours with AR. Those EGFR mutant tumours harbouring completely inactivated Rb and p53 have a 43 times greater risk of small-cell transformation [8] . These transformed SCLC tumours express neuroendocrine markers, maintain the original EGFR-sensitizing mutation and respond to standard SCLC chemotherapy [3] .
Knowledge of AR mechanisms to EGFR TKIs was one of the triggers behind the development of third-generation EGFR-TKIs, which are active against exon 19 and 21 mutations as well as the T790M mutation. Among them, osimertinib (AZD9291) was the first to receive FDA and EMA approval in November 2015 and February 2016, respectively, for metastatic EGFR-mutant and acquired EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) patients [9, 10] progressing on or after EGFR TKI therapy. This article provides an overview of preclinical and clinical data on osimertinib and other third-generation EGFR TKIs currently in development. The potential use of osimertinib in the adjuvant setting and the combination of EGFR TKIs with immune checkpoint inhibitors in resistant EGFR-mutation NSCLC patients will be also reviewed.
Osimertinib
Osimertinib is a mono-anilino-pyrimidine compound that specifically binds to the EGFR kinase domain irreversibly by targeting the cysteine-797 residue in the ATP binding site via covalent bond formation. In cell lines, osimertinib potently inhibited phosphorylation of EGFR in PC-9 (Del19) and H3255 (L858R) cell lines with mean IC 50 values ranging from 13 to 54 nmol/l. In H1975 (L858R/T790M) and PC-9 VanR (Del19/ T790M) resistant cell lines, activity of osimertinib was reported with mean IC 50 potency of <15 nmol/l (Table 1 ) [11] . Osimertinib is more selective to the mutated receptor as evidenced by a high IC 50 (range from 480 to 1865 nmol/l) in inhibiting phosphorylation of EGFR in wild-type cell lines. Interestingly, osimertinib was not potent against lines harbouring non-T790M resistance mechanisms, such as MET amplification or NRAS [11] .
Osimertinib is metabolized to produce at least two circulating metabolites, AZD5104 and AZD7550. In biochemical assays, AZD7550 had a comparable potency and selectivity profile to osimertinib, although AZD5104 showed greater potency against EGFR Del19, T790M mutations (both $8-fold) and wild-type EGFR ($15-fold) [11] . In tumour xenograft and transgenic mouse models harbouring sensitizing and resistance EGFR mutations, osimertinib exposure resulted in a profound and sustained tumour regression [11] . Due to the higher selectivity to the mutated receptor, osimertinib is associated with less severe gastrointestinal and skin toxicity compared with first-or secondgeneration EGFR TKIs [12] . Mean half-life of osimertinib is 48.3 h with minimal food effect on exposure and no differences according to ethnicity (Asian and Non-Asian), body weight, sex or age [13] . Additionally, data from a pharmacokinetic study (NCT02163733) showed that administration of omeprazole does not have an effect on osimertinib exposure [14] .
Clinical activity with osimertinib
Phase I experience A phase I/II dose escalation study of osimertinib (AURA, NCT01802632) was carried out in patients with locally advanced or metastatic EGFR-mutant NSCLC patients who had disease progression on previous treatment with an EGFR TKI [15] . The study included dose-escalation and dose-expansion cohorts. Patients were only preselected according to T790M status in the expansion cohort. Sequential cohorts of patients (N ¼ 253) received five dose levels of osimertinib ranging from 20 to 240 mg daily. Among 31 patients in the dose-escalation cohort, no doselimiting toxicity was observed and the maximum tolerated dose was not reached. An additional 222 patients were treated in five dose-expansion cohorts. The T790M was detected in 138 patients (62%), not detected in 62 patients (28%), and of unknown status in 22 patients (10%) [15] . Of the 253 patients treated across all dose levels, 239 were assessable for response. The ORR and disease control rate (DCR) in the whole population were 51% [95% confidence interval (CI), [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] and 84% (95% CI, 79-88), respectively, without differences according to ethnicity. The median PFS was 8.2 months. Among the 138 patients with centrally confirmed T790M mutations, 127 patients were assessable for response. Outcomes were substantiality better in T790M-positive tumours compared with T790M-negative tumours, with an ORR of 61% (95% CI, 52-70) versus 21% (95% CI, 12-34), a DCR of 95% (95% CI, 90-98) versus 61% (95% CI, and median PFS of 9.6 months (95% CI, 8.3 to not reached) versus 2.8 months (95% CI, 2.1-4.3), respectively [15] . The most common adverse events (AEs) were diarrhoea (47%), skin toxicity (rash/acne 40%), nausea (22%) and decreased appetite (21%), and the majority of these were grade 1 or 2 in severity. The 80 mg daily dose was selected as the recommended dose for further clinical trials based on its optimal therapeutic index [15] (Table 2) .
In an updated report of the dose expansion cohort in the AURA trial (NCT01802632) with osimertinib 80 mg daily in patients with centrally confirmed T790M-positive NSCLC, 61 of 63 patients were assessable for response. The ORR was 71% (95% CI, 57-82) and median PFS was 9.7 months (95% CI, 8.3-13.6) [16] .
Phase I extension and phase II studies with osimertinib
Further confirmation of the efficacy and safety of osimertinib 80 mg daily was provided by the extension part of the AURA study in 201 T790M-positive advanced NSCLC patients [17] . The ORR and DCR was 62% (95% CI, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] and 90% (95% CI, 85-94), respectively. Median PFS was 12.3 months (95% CI, 9.5-15.5), with 12-month PFS and OS of 52% and 79%, respectively (Table 2) . Subset PFS analysis did not report differences according to line of therapy, EGFR-mutation subtype, ethnicity or previous exposure to EGFR TKIs. The most common casually related AEs were diarrhoea (43%; grade ! 3, <1%) and rash (grouped terms; 40%; grade ! 3, < 1%). Interstitial lung disease (ILD) was reported in 4% of patients (n ¼ 8, grade 3-5 in six patients). Among those patients with asymptomatic and stable brain metastases (n ¼ 74), median PFS was shorter compared with those patients without brain metastases (7.1 versus 13.7 months). In the CNS response analysis set, the ORR was 64% [17] , suggesting encouraging results with osimertinib in EGFR-mutant NSCLC patients with brain metastases. The phase II AURA2 trial (NCT02094261) demonstrated similar results [18] ( Table 2 ). The study enrolled 210 T790M-positive metastatic NSCLC patients who had progressed after previous therapy with an approved EGFR TKI. The ORR and DCR were 70% (95% CI 64-77) and 92% (95% CI 87-95), respectively, including patients with CNS metastases. Overall, median PFS was 9.9 months (95% CI, 8.5-12. 3), with 6-and 12-month PFS of 71% and 44%, respectively. The most common all-causality grade 3 and 4 AEs were pulmonary embolism (3%), prolonged electrocardiogram QT (2%), decreased neutrophil count (2%), anaemia, dyspnoea, hyponatremia, increased alanine aminotransferase, and thrombocytopenia (1%, each) [18] .
A pre-planned pooled analysis of AURA extension [17] and AURA2 trial [18] was carried out and included 411 patients (129 patients at second-line and 282 as third-line or beyond). The ORR was 66% (95% CI, 67-71), with median duration of response of 12.3 months (95% CI, 11.1-13.8). Pooled median PFS and OS were 9.9 and 26.8 months, respectively. At 12 and 24 months, 80% and 56% of patients were alive, respectively. The most common (investigator assessed) possibly causally related AEs were rash [grouped term 42%, (grade 3, 1%)] and diarrhoea [39% (<1%)]. Four patients died due to possibly causally related toxicity [19] .
Comparison of osimertinib to chemotherapy
The robust efficacy of osimertinib in patients with T790M-mediated AR resulted in accelerated approval by the FDA in November 2015. Recently, the results of the confirmatory phase III study of osimertinib versus platinum-based chemotherapy were reported. The AURA3 (NCT02151981) was an open-label randomized phase III trial in second-line setting [20] , comparing osimertinib to platinum plus pemetrexed (up to six cycles and followed by optional pemetrexed maintenance) for patients with centrally confirmed T790M-positive advanced NSCLC after firstline EGFR TKI. The trial enrolled 419 patients with 60% of patients in the chemotherapy arm crossing over to receive osimertinib at progression. Osimertinib significantly improved PFS compared with chemotherapy [10.1 versus 4.4 months, hazard ratio (HR) 0.30; 95% CI, 0.23-0.41, P < 0.0001], and ORR (71% versus 31%, P < 0.001, Table 2 ). Grade 3 AEs were lower with osimertinib (23% versus 47%). In the osimertinib group, the most common AEs reported were diarrhoea (41%), rash (34%), dry skin (23%) and paronychia (22%). ILD-like AEs were reported in 4% of patients. Data on OS are not yet available [20] . These results clearly demonstrate the efficacy of osimertinib as standard treatment in T790M-positive NSCLC patients after disease progression on a first-or second-generation EGFR TKI.
Osimertinib as first-line therapy
In EGFR TKI-naive patients, de novo T790M mutations were described with variable frequency, ranging from <1% to 80%, depending on detection method [21] [22] [23] , and predict for less benefit to reversible EGFR TKIs [24, 25] . Unlike gefitinib or afatinib, chronic treatment with osimertinib did not cause AR in PC-9 cells in vitro through gain of T790M [26] . Therefore, upfront osimertinib therapy for patients with an activating EGFR mutation could avoid this mechanism of resistance, given its superior potency against T790M.
In the phase I AURA trial, 60 treatment-naive patients with metastatic EGFR-mutant NSCLC (77% T790M-negative) received upfront osimertinib at 80 mg/day (N ¼ 30) or 160 mg/ day (N ¼ 30). According to treatment dose group, 80 and 160 mg, the ORR was 67% and 87% (77% across doses) and PFS was 22.1 and 19.3 months (20.5 months across doses), respectively [27] . These results are encouraging relative to the efficacy of gefitinib or afatinib in the first-line setting [28, 29] and suggest osimertinib as a potential option in the first-line setting, independent of T790M-status. The phase III FLAURA trial (NCT02296125) compared osimertinib to erlotinib or gefitinib (standard of care) as first-line treatment in patients with advanced NSCLC and common EGFR mutations. Patients with stable CNS metastases were allowed. In the control arm, cross-over to osimertinib was allowed in case of disease progression and confirmation of T790M mutation-based resistance. The primary end point of the trial was PFS. Among 556 patients enrolled ($20% with brain metastases), a significant improvement in PFS (18.9 versus 10.2 months, HR 0.46, P < 0.0001) was reported with osimertinib irrespective of race or EGFR mutation subtype compared with standard of care. Osimertinib also improved the systemic PFS in patients with brain metastases compared with standard of care (15.2 versus 9.6 months, HR 0.47, P ¼ 0.0009). There were no differences in ORR (80% versus 76%), but osimertinib resulted in a two-fold increase in the median duration of response (17.2 versus 8.5 months). OS data were immature but preliminary results showed promising results (HR 0.63, P ¼ 0.00068) in favour of osimertinib, despite the fact that cross-over was allowed. Lower grade !3 AEs (34% versus 45%) and a lower discontinuation rate were reported with osimertinib compared with standard of care treatment [30] . These results suggest osimertinib as a new standard in first-line treatment of patients with EGFR-mutant advanced NSCLC.
Recently, mechanisms of AR to osimertinib as first-line treatment have been described in cell-free DNA samples from 19 patients included in the phase I AURA trial cohort. Putative genomic resistance mutations were identified in 9 of 19 patients with detectable circulating tumour DNA (ctDNA). There was no evidence of acquired T790M mutation in any plasma ctDNA sample analysed. Two cases of acquired EGFR C797S resistance mutations were detected: one in a patient with a de novo T790M mutation, and one in the absence of T790M. Also, an acquired MEK1 G128V variant, HER2 exon 20 insertion, JAK2 V617F and MET copy number gains have been described as mechanisms of AR with upfront osimertinib [27] . However, no specific treatment strategies have been established at osimertinib resistance. In preclinical models, if the C797S mutation develops in cells wildtype for T790M (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs [31] . Efficacy, toxicity and treatment options after osimertinib resistance may help to define the best strategy for sequencing upfront EGFR TKI in this population.
Osimertinib efficacy in central nervous system metastases
Globally, the incidence of brain and leptomeningeal metastases among EGFR-mutant NSCLC patients is 31% [32] and $9% [33] [34] [35] , respectively. Erlotinib [36] , gefitinib [37] and afatinib [38] have a modest degree of intracranial activity. However, preclinical data demonstrated greater penetration and brain exposure with osimertinib than with gefitinib, rociletinib or afatinib [39] . CNS activity of osimertinib had been reported in the AURA study phase II extension component [17] , the phase II AURA2 trial [18] , and was recently confirmed in the phase III AURA3 trial. In the phase III AURA3 trial, among 144 patients with stable and asymptomatic brain metastases, PFS was also longer with osimertinib compared with chemotherapy (8.5 versus 4.2 months, HR 0.32; 95% CI, 0.21-0.49) [20] . Among those patients with CNS disease assessable for response (n ¼ 46), CNS ORR was 70% with osimertinib compared with 31% with chemotherapy with a median duration of response of 8.9 versus 5.7 months, respectively. Also, the cumulative incidence of CNS progression at 6 months was lower with osimertinib compared with chemotherapy (11.5% versus 28.2%) [40] . AURA3 confirmed the CNS efficacy of osimertinib, with higher and more durable responses while also delaying the onset of brain metastases in this population. A phase II trial (NCT 02971501) assessed the PFS of osimertinib with or without bevacizumab. Indeed, preliminary results from the phase I (BLOOM) trial have reported long-lasting clinical and radiological activity of osimertinib at 160 mg among 21 EGFR TKI pre-treated EGFR-mutant NSCLC patients with leptomeningeal metastases (cytologically confirmed) and controlled extracranial disease. Baseline T790M mutation was detected in cerebrospinal fluid in two patients and in plasma in six [41] . The ongoing phase II (BLOOM) study (NCT02228369) is enrolling T790M-positive (tested in plasma or tissue) NSCLC patients with leptomeningeal disease. Globally, these results endorse the efficacy of osimertinib in cerebral nervous system metastases among T790M-positive NSCLC patients.
T790M detection in plasma ctDNA in osimertinib studies
Liquid biopsies based on ctDNA analysis have been described as surrogate samples for molecular analysis replacing molecular analysis of tumour tissue [42] and may allow real-time sampling of multifocal clonal evolution [43, 44] . Also, ctDNA analysis can be used to monitor clonal evolution [45] and identify mechanisms of AR to treatment [44] . Retrospective exploratory analyses have reported that acquired T790M mutations (tested by cobas EGFR Mutation Testv2) among EGFR-mutant NSCLC patients was detected in 50% of patients, in concordance with tumour biopsy-derived genotyping which was 61% [46] . Among patients with sufficient material for concurrent ctDNA and tumourderived genotyping, ctDNA identified the T790M mutation in 5 of 25 (20%) patients in whom the concurrent tissue biopsy was negative [46] . Recently, the cobas plasma EGFR Mutation Testv2 detected the T790M mutation in 61% of tumour tissue T790M mutation-positive patients from AURA extension and AURA phase II trials [47] . New techniques are being developed to increase the sensitivity of detecting EGFR sensitizing and resistance EGFR-mutations [48] .
A retrospective analysis from the AURA I trial demonstrated that patients who were T790M positive in plasma had outcomes with osimertinib that were equivalent in RR and PFS to patients found to be positive by a tissue-based assay. Indeed, T790M was detected in plasma in 31% of T790M-negative tumours [49] . In the AURA3 trial, patients with T790M-positive status on both tumour and plasma analysis (n ¼ 172) had an RR of 77% with osimertinib, and median PFS with osimertinib was 8.2 months compared with 4.2 with chemotherapy (HR 0.42, 95% CI, 0.29-0.61), an outcome improvement similar to that in the intent-totreat population [20] . However, all these data are retrospective and in a population with a known T790M status in the tumour.
Prospective validation of liquid biopsy as a surrogate marker for making treatment decisions has started to emerge. Recently, in a cohort of heavily pretreated EGFR-mutant NSCLC patients with progression and unknown T790M status in the tumour were prospectively treated on the basis of the ctDNA analysis. Those patients with T790M positivity in plasma achieved an ORR of 62.5% and 6-month PFS of 66.7%, similar to those patients treated on the basis of tissue analysis [50] . Interestingly, responses were also seen in patients with very low allele fractions of T790M mutation in plasma (<0.5%) [50] . Liquid biopsies also have the potential to function as dynamic surrogate markers of treatment efficacy. Clearance of plasma EGFR mutations after 6 weeks of osimertinib therapy was found to be associated with improved RR (70% versus 35%) and median PFS (10.9 versus 5.5 months) among 143 patients with T790M-positive NSCLC included in the phase I AURA trial (NCT01802632) [51] . These results support the feasibility of detecting T790M from plasma ctDNA samples for making treatment decisions and evaluating efficacy. Additionally, a recent algorithm for plasma and tissue T790M testing in patients with AR has been proposed, suggesting that those patients with a negative plasma result should undergo a tissue test [49, 52] . At the present time, EMA and FDA have accepted the use of information from ctDNA analysis to help to select EGFR-mutant NSCLC patients for osimertinib [9, 10].
Future directions Optimal sequence of TKIs
As therapeutic options for this patient population, the issue of optimal sequencing of available agents is still an important question. Moreover, it is unknown whether switching treatment according to molecular progression (i.e. ctDNA T790M mutation positivity without RECIST progression) instead of RECIST progression could have an impact on treatment outcomes. Based on the predictive value of liquid biopsies, the three-arm phase II APPLE trial (NCT02856893) [53] in treatment-naive and common EGFR mutation NSCLC patients will explore upfront osimertinib, upfront gefitinib switching to osimertinib in case of T790M-positivity in plasma and upfront gefitinib and switching to osimertinib according to RECIST criteria regardless of T790M status. The primary end point of the trial is 18-month PFS on osimertinib for assessing whether liquid biopsies could become the new standard procedure for defining disease progression versus RECIST progression in this population and also assessing whether a sequenced strategy is more appropriate than upfront osimertinib.
Dual vascular endothelial growth factor receptor and EGFR blockade inhibit tumour growth in EGFR TKI resistance xenograft models [54] . Two phase II clinical trials have reported improvement in outcome with erlotinib plus bevacizumab combination as first-line treatment in EGFR-mutant NSCLC patients [55, 56] . Combination of osimertinib and bevacizumab as first-line strategy is being tested in a phase I/II clinical trial (NCT02803203) and osimertinib and ramucirumab as a secondline strategy among T790M-positive tumours in a phase I clinical trial (NCT02789345).
Osimertinib in the adjuvant setting
The role of EGFR TKIs in patients with early NSCLC has not been defined [57, 58] . Following surgical resection, adjuvant platinum-based chemotherapy remains the standard of care, even for patients with an activating EGFR mutation. The ADAURA trial (NCT02511106) is a double-blind, randomized, placebo-controlled trial that will study the efficacy of osimertinib in 700 completely resected EGFR-mutant stage IB-IIIA NSCLC patients after adjuvant chemotherapy. The primary end point of the study is disease-free survival. The study is presently accruing patients.
Osimertinib and immune checkpoint inhibitors
Immune checkpoint inhibitors are considered the standard second-line treatment in advanced NSCLC patients based on survival improvement reported in four randomized phase III clinical trials [59] [60] [61] [62] . Recently, another phase III trial has reported significant improvement in PFS and ORR with pembrolizumab as first-line treatment compared with standard platinum-based chemotherapy among tumours with high PD-L1 expression (! 50%) [63] . However, a recent meta-analysis has reported lack of survival benefit with these agents among EGFR-mutant tumours [64] and a retrospective study has reported lower RR with immune checkpoint inhibitors in EGFR-mutant versus EGFRwild-type NSCLC patients [65] . The lack of association with smoking and the limited mutational tumour burden of EGFRmutant tumours [66, 67] may explain the lack of efficacy among this population.
Preclinical data have reported T790M-positive tumours as immunogenic [68] , and tumours with AR to EGFR TKIs express higher levels of PD-L1 than sensitive tumours [69] . However, in the clinic, T790M mutation correlates with lower PD-L1 expression and PD-L1 expression was a negative prognostic factor [70] . EGFR-mutant NSCLC patients and T790M-negative tumours were more likely to benefit from nivolumab after EGFR-TKI treatment, probably as a result of higher PD-L1 expression than is present in T790M-positive patients [71] . Other trials testing the combination of osimertinib and immune checkpoint inhibitors, such as the phase III CAURAL trial (NCT02454933) and the multi-arm phase IB TATTON trial (NCT02143466) investigating osimertinib (80 mg/d) in combination with durvalumab (anti-PD-L1 monoclonal antibody), were stopped for safety concerns regarding increased incidence of ILD. Exploratory analysis from the TATTON trial (n ¼ 34) reported encouraging clinical activity with RR of 67% in 9 patients with T790M-positive tumours compared with 21% in 14 T790M-negative NSCLC. ILD was reported in 38% of patients, which is higher than would be expected with either drug alone, including five patients (15%) with grade 3-4 events [72] . Results from the other two arms in the TATTON trial (osimertinib plus selumetinib and osimertinib plus AZD6094) are awaited.
Other third-generation EGFR TKIs
Rociletinib and olmutinib are other third-generation TKIs in development. Rociletinib has demonstrated promising results with a 59% ORR for patients with an activating EGFR mutation and the T790M mutation. However, updated data decreased the observed ORR to 28-34% [73] . This decrease, along with toxicity issues such as hyperglycaemia, led to halting of the clinical development of rociletinib. Olmutinib also demonstrated initial successes with ORR of 56% and median PFS of 8.3 months in T790M-positive NSCLC patients [74] . While it was initially approved in South Korea, its clinical development is currently uncertain, as two cases of toxic epidermal necrolysis and one case of Stevens-Johnson syndrome have been reported.
However, there are several other third-generation EGFR TKIs currently in clinical development. Avitinib is a third-generation irreversible EGFR TKI that targets both EGFR activating mutations as well as the T790M mutations. Enrolment is currently ongoing in a phase I trial for patients who progress on a firstgeneration EGFR TKI, with or without the T790M mutation. Overall, the drug has been well tolerated and ORR for 48 assessable patients was 41.7% with a DCR of 87.9% [75] . The drug ASP8273 is also an irreversible EGFR TKI that targets the T790M mutation. Preliminary results from the phase I study have been reported; 60 patients have been enrolled and no dose-limiting toxicities were noted. ORR is 36% and the median PFS is 6.7 months [76] . However, the phase III SOLAR trial (NCT02588261) comparing ASP8273 with erlotinib or gefitinib as first-line treatment in EGFR-mutant NSCLC patients has been discontinued and no further development programs for ASP8273 have been announced. The phase I with the EGFR TKI EGF816 enrolled 127 patients with a T790M mutation that could be evaluated for response, with an ORR of 44% and estimated PFS of 9.2 months [77] . Finally, the EGFR TKIs PF-06747775 and AZD3759 are at an early stage in clinical development. Interestingly, AZD3739 was specifically designed to penetrate the blood-brain barrier, as CNS metastasis is a common location of progression for EGFR patients. The early data are promising for this patient population, with 40% of patients demonstrating CNS tumour shrinkage [78] . Further studies are ongoing for these drugs and will potentially increase the therapeutic options.
Discussion Conclusion
Osimertinib is the first FDA and EMA approved third-generation EGFR TKI and has proven to be both well-tolerated and effective in patients with the acquired T790M resistance mutation, significantly improving the treatment options for this disease. The results of the FLAURA study support the use of osimertinib as first-line therapy and represent a new standard for this patient population. Further research into how to improve on these findings are currently under way, including combining osimertinib with other drugs, examining its use in adjuvant settings and furthering research into resistance mechanisms. The development of osimertinib has clearly improved the therapeutic landscape for EGFR-mutant NSCLC and presents exciting opportunities for clinicians and patients.
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